Short Interest in Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Grows By 55.8%

Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) was the target of a large increase in short interest in March. As of March 31st, there was short interest totaling 112,375 shares, an increase of 55.8% from the March 15th total of 72,125 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average trading volume of 17 shares, the short-interest ratio is presently 6,610.3 days.

Newron Pharmaceuticals Price Performance

Newron Pharmaceuticals stock opened at $20.00 on Thursday. The company has a fifty day moving average price of $11.91 and a two-hundred day moving average price of $10.25. Newron Pharmaceuticals has a 12 month low of $9.10 and a 12 month high of $20.00.

Newron Pharmaceuticals Company Profile

Newron Pharmaceuticals SpA is a clinical-stage biopharmaceutical company headquartered in Bresso, Italy, dedicated to developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts focus on small-molecule compounds designed to address unmet medical needs in neurology and psychiatry.

Newron’s lead product, safinamide, is marketed under the brand name Xadago as an adjunctive therapy for patients with mid- to late-stage Parkinson’s disease.